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Abstract: Primary care integration of Down syndrome (DS)-specific dementia screening is strongly 
advised. The current study employed principal components analysis (PCA) and classification and 
regression tree (CART) analyses to identify an abbreviated battery for dementia classification. Scale- 
and subscale-level scores from 141 participants (no dementia n = 68; probable Alzheimer’s disease 
n = 73), for the Severe Impairment Battery (SIB), Dementia Scale for People with Learning Disabili-
ties (DLD), and Vineland Adaptive Behavior Scales—Second Edition (Vineland-II) were analyzed. 
Two principle components (PC1, PC2) were identified with the odds of a probable dementia diag-
nosis increasing 2.54 times per PC1 unit increase and by 3.73 times per PC2 unit increase. CART 
analysis identified that the DLD sum of cognitive scores (SCS < 35 raw) and Vineland-II community 
subdomain (<36 raw) scores best classified dementia. No significant difference in the PCA versus 
CART area under the curve (AUC) was noted (D(65.196) = −0.57683; p = 0.57; PCA AUC = 0.87; CART 
AUC = 0.91). The PCA sensitivity was 80% and specificity was 70%; CART was 100% and specificity 
was 81%. These results support an abbreviated dementia screening battery to identify at-risk indi-
viduals with DS in primary care settings to guide specialized diagnostic referral. 
Keywords: Down syndrome; dementia; cognition; functional independence; neuropsychological as-
sessment; primary care; screening 
 
1. Introduction 
Down syndrome (DS), a genetic condition caused predominantly by the triplication 
of chromosome 21, is highly associated with the development of Alzheimer’s disease (AD) 
[1]. Chromosome 21 includes the amyloid precursor protein (APP) gene, and triplication 
results in overexpression of APP and related proteins, accelerating the accumulation of 
misfolded amyloid in the brain [2–4]. Additional AD risk factors are also associated with 
DS including a higher propensity for neuroinflammation, oxidative damage, sleep apnea, 
and reduced cognitive reserve due to premorbid intellectual disability [1,5–7]. Indeed, AD 
pathological changes have been documented in adults with DS as young as 20 years, and 
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nearly all adults with DS show the amyloid plaques and neurofibrillary tangles associated 
with AD by 40 years of age [8–10]. 
DS is associated with different physical morphology, intellectual disabilities, and re-
duced lifespan compared to the typically developing population. Associated health prob-
lems include atlantoaxial instability, musculoskeletal and dental conditions, congenital 
heart disease, hematologic conditions, obesity, hypothyroidism, obstructive sleep apnea, 
impaired hearing and vision, and overall increased functional dependence due to behav-
ioral, psychiatric, and intellectual impairments [7,11–14]. Advances in medical manage-
ment of these co-morbidities have lowered mortality from early-life conditions, but one 
consequence of lengthened lifespan is that more individuals with DS now survive to the 
age of risk for AD [15]. 
Due to the need for preventative care and ongoing management of chronic health 
conditions associated with DS, health professionals and advocacy groups recommend the 
integration of DS-specific care in primary care settings [14,16,17]. Healthcare systems have 
made progress toward this end, but there is a need for improvement [11,18]. Cognitive 
screening and monitoring for dementia is particularly difficult, as cognitive measurement 
is complicated by pre-existing intellectual disability (ID), large inter- and intra-individual 
variability in cognition and behavior, tolerability of testing methods, and the lack of an 
identified “gold standard” neurocognitive battery, even for research purposes [19,20]. 
Moreover, neurocognitive tests are not feasible in primary care settings due to the lengthy 
procedures and specialized training needed for the interpretation of comprehensive eval-
uations. 
In recent studies, our group has sought to establish an evidence base for abbreviated 
neurobehavioral examination procedures appropriate for in-office dementia monitoring 
by community practitioners caring for patients with DS [21]. Performance measures in our 
long-term cohort studies include the Brief Praxis Test (BPT) [22] and the Severe Impair-
ment Battery (SIB) [23]. Informant measures included the Dementia Questionnaire for 
People with Learning Disabilities (DLD) [24] and Vineland Adaptive Behavior Scales-Sec-
ond Edition (Vineland-II) [25]. The BPT, SIB, and DLD have all been used in early DS 
clinical trials assessing the effects of anticholinesterase therapy [26] as well as antioxidants 
[27,28]. Moreover, the SIB has long been validated as a cognitive measure for severe im-
paired individuals with AD [29]. The Vineland-II has been widely used and validated in 
the DS population [30–32] and adaptive behavior decline is a diagnostic criterion for AD, 
necessitating the inclusion of this type of measure in this study. These measures were 
selected at the outset of the two parent cohorts from which the present data are drawn, 
and target the domains of cognition (SIB, DLD), praxis (BPT), and functional independ-
ence (DLD, Vineland-II) that underlie both NINCDS-ADRDA and DSM-IV criteria for de-
mentia/major neurocognitive disorder. 
The present study seeks to further identify the key components that are useful for 
dementia detection through three aims: 
• Aim 1: to identify the underlying components of a cognitive battery that was used to 
assess functioning in domains commonly affected by AD. 
• Aim 2: to select the minimum necessary individual items or subscales using CART 
analysis to create an abbreviated battery for classifying AD status.  
• Aim 3: to compare the classification accuracy between the two methods: components 
from the full battery vs. the abbreviated battery. 
2. Materials and Methods 
2.1. Description of Sample 
The current study combines participants from cohorts at two different sites: the Uni-
versity of Kentucky and the University of California, Irvine (UCI). The University of Ken-
tucky Aging and Down Syndrome (ADS) study is a longitudinal cohort of aging individ-
uals with DS. For the purpose of the current study, only the baseline visit was used for 88 
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participants. Twenty-nine of the original one hundred and seventeen participants in the 
overall ADS study were unable to contribute data for the present analysis, predominantly 
due to inability to engage in testing because of advanced dementia. The University of 
Kentucky ADS cohort recruited individuals with DS between 25 and 64 years of age. From 
the UCI cohort, only the baseline visit was used for 53 participants. One of the original 54 
participants in the overall UCI study was unable to contribute data for the present analysis 
due to inability to engage in testing because of advanced dementia. The UCI cohort in-
cluded people between 43 and 58 years of age.  
A karyotype diagnosis of trisomy 21 (full or mosaic) or the Robertsonian transloca-
tion form of DS was required. Baseline levels of ID were determined by caregiver report 
of prior evaluation results or by a review of records when available. Other requirements 
for study inclusion included a stable medical condition for at least 3 months prior to the 
study and to have an absence of systemic disorders that might confound a diagnosis of 
dementia. Medication usage including psychotropic and Parkinsonian drugs was re-
quired to be stable for 3 months prior to study, and English-speaking skills were required 
to facilitate neuropsychological testing. 
Research procedures were independently reviewed and approved by the University 
of Kentucky Institutional Review Board and the UCI Institutional Review Board. Partici-
pants completed approved protocols for informed consent or assent with guardian or le-
gally authorized representative approval.  
2.2. Description of Measures  
Both sites administered a combination of performance and informant measures that 
have been used with adults with DS. Performance measures included the BPT and SIB, 
and informant measures included the DLD and Vineland-II.  
The BPT is a 20-item measure of dyspraxia that minimizes verbal demands in favor 
of simple behavioral output. Low scores on the BPT indicate severe dyspraxia.  
The SIB utilizes one-step commands and gestural cues, and allows for non-verbal 
responses and partially correct responses in order to assess cognition in individuals with 
severe dementia. The SIB yields a total score along with six major subscales for attention, 
orientation, language, memory, visuospatial ability, and construction, with additional 
scores for orientation to name, praxis, and social interaction. Lower scores indicate more 
severe deficits.  
The DLD is a 50-item informant questionnaire measuring behavioral and cognitive 
dysfunction. The DLD yields three scores: (1) sum of cognitive score (SCS), measuring 
short-term memory, long-term memory, and spatial/temporal orientation; (2) sum of so-
cial score (SOS), measuring speech, practical skills, mood, activity/interest, and behavioral 
disturbance; and (3) a total score that combines the SCS and SOS. DLD raters for the cur-
rent study were caregivers and/or legal guardians responsible for the daily care of the 
participants either at home or an assisted living facility. Higher scores on the DLD indicate 
more severe impairment.  
The Vineland-II is an informant-based measure covering domains of communication, 
daily living skills, socialization, motor skills, and maladaptive behavior. The Vineland-II 
provides a composite score reflecting an individual’s overall adaptive behavior function-
ing, called the Adaptive Behavior Composite (ABC). The Vineland-II is administered by a 
trained interviewer to the parent or caregiver.  
2.2.1. Consensus Diagnosis 
AD diagnosis, based on NINCDS-ADRDA or DSM-IV criteria [33,34], was made at 
each site using a consensus process involving a neurologist and a psychologist. The SIB, 
BPT, and DLD test data were used in consensus diagnosis decisions. The diagnosis of de-
mentia required a clinical and neurological examination showing deficits in 2 or more 
areas of cognitive functioning, and progressive worsening of cognitive performance com-
pared to the potential participant’s baseline functioning.  
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2.2.2. Data Preparation 
Raw scores were used for all measures except for the Vineland-II domain-level scores 
(ABC, communication, daily living skills, socialization, and motor skills), which were only 
available as standardized scores. No subscales were removed for excessive missingness 
(>15% of data points missing across individuals). The DLD had the least amount of miss-
ing data (0.71% missing), followed by the Vineland-II (9.22% missing) and the SIB (9.93% 
missing). Missing data were imputed using chained random forests via the ‘missRanger’ 
R package [35]. Next, the DLD scores were inverted for consistent directionality with the 
other measures. All analyses were completed in R v 4.0.0 [36] and the significance level 
set to 0.05. 
Aim 1: Principal Components Analysis 
For the first aim, principal components analysis (PCA) was used to identify the num-
ber of components assessed by all individual items from the performance and informant 
procedures. The R package ‘tidymodels’ was used for all steps of the PCA analysis. The 
appropriateness of using PCA was evaluated using variable correlations, Bartlett’s test, 
Kaiser-Meyer-Olkin, and determinants. In terms of correlations, variables should be only 
mildly intercorrelated and were examined using thresholds suggested by Field et al. [37] 
to have absolute correlations ranging from 0.3 to 0.9. Items with more than one occurrence 
for a correlation outside of the range were excluded from the PCA analysis. Only four 
variables needed to be excluded: Vineland-II ABC, Vineland-II social domain score, one 
item from the Vineland-II maladaptive behavior domain scale, and the SIB total score. The 
Kaiser-Meyer-Olkin factor adequacy was 0.95, above the 0.7 threshold. Bartlett’s test of 
sphericity was significant (X2(325) = 5207.62; p < 0.001). Finally, the determinant was below 
0.00001. Together, these indicated that PCA was appropriate. Based on the scree plot of 
unrotated results, two components with eigenvalues > 1.0 were identified, accounting for 
76% of the total variance in scores. Varimax rotation of loadings was then employed to 
enhance interpretability of identified components. 
The dataset containing the two components scores and AD diagnostic status were 
then split into a training and test dataset. The training dataset was used to generate the 
logistic regression model. The model was assessed for multicollinearity and the assump-
tion that independent variables are linearly related to the log odds. The performance of 
the generated model was assessed on the test dataset by evaluating the area under the 
curve (AUC), sensitivity, and specificity.  
Aim 2: Classification and Regression Tree Analysis 
For the second aim, classification and regression tree (CART) modeling was used to 
identify an optimal set of rules for classifying participants by diagnosis based only on 
item- and subscale-level data from the neurobehavioral battery. Again, R package ‘tidy-
models’ was used in all steps of the CART analysis. First, training and test datasets were 
generated from the data. Then, the training dataset was used to generate a set of 10-fold 
cross-validation samples for model hyperparameter tuning. The best hyperparameters 
were selected based on the AUC. The CART model was first fit on the training dataset, 
then on the test dataset to assess performance.  
Aim 3: Receiver Operating Characteristic Curves and Comparisons 
For the third aim, to compare the relative utility of the PCA and CART models, the 
AUC of both models for classifying diagnosis were compared using the bootstrap test for 
comparing ROC curves (R routine ‘roc.test’ from the package ‘pROC’). Sensitivity, speci-
ficity, and positive and negative predictive values were computed for the PCA and CART 
models. 
  




3.1. Sample Characteristics 
A total of 141 participants were included in the current study. Just over half of the 
participants (n = 73; 51.77%) were diagnosed with probable AD. Full participant charac-
teristics are provided in Table 1. 
Table 1. Participant Characteristics. 
Characteristic No Dementia, N = 68 Probable AD, N = 73 Overall, N = 141 
Sex    
Female 36 (52.94%) 41 (56.16%) 77 (54.61%) 
Male 32 (47.06%) 32 (43.84%) 64 (45.39%) 
Age (years) 38.11 (9.34) 52.68 (6.12) 45.66 (10.70) 
Level of Intellectual 
Disability (esti-
mated) 
   
Mild 3 (4.41%) 14 (19.18%) 17 (12.06%) 
Moderate 36 (52.94%) 29 (39.73%) 65 (46.10%) 
Profound 28 (41.18%) 15 (20.55%) 43 (30.50%) 
Severe 1 (1.47%) 13 (17.81%) 14 (9.93%) 
Unknown 0 (0.00%) 2 (2.74%) 2 (1.42%) 
Site    
UCI 0 (0.00%) 53 (72.60%) 53 (37.59%) 
UKY 68 (100.00%) 20 (27.40%) 88 (62.41%) 
n (%); mean (SD). 
3.2. Aim 1: Principal Components Analysis Results 
Results of the PCA are listed in supplementary Table S1. The two components could 
not be easily labeled because they each contained items from communication, daily living 
skills, and cognitive domains. For the PCA method, logistic regression results demon-
strated that higher scores on PC1 and PC2 were predictive of AD diagnosis. For each unit 
increase in PC1, the odds of a probable dementia diagnosis increased 2.54 times, and for 
each unit increase in PC2 the odds of a probable dementia diagnosis increased 3.73 times 
(Table 2). 
Table 2. Logistic Regression. 
Predictors Odds Ratio 95% CI p 
(Intercept) 1.14 0.46–2.84 0.773 
PC1 2.54 1.69–3.81 <0.001 
PC2 3.73 1.62–8.60 0.002 
Observations 106   
Tjur’s R2 0.786   
n (%); mean (SD). 
3.3. Aim 2: Classification and Regression Tree Analysis Results  
The CART analysis revealed that the DLD SCS and Vineland-II community subdo-
main raw scores best-classified dementia (Figure 1). A DLD SCS less than 35 and a Vine-
land community score less than 34 are indicative of AD dementia. 




Figure 1. Results of CART analysis. Note. AD = Alzheimer’s disease; DLD SCS = Dementia Questionnaire for People with 
Learning Disabilities (DLD) sum of cognitive scores raw score; CMM Raw = Vineland-II community subdomain raw score. 
3.4. Aim 3: Comparison of PCA and CART Model Classification Utility 
Comparing the PCA logistic regression and CART classification methods, there was 
no significant difference in AUC (D(65.196) = −0.57683; p = 0.57) (Figure 2). The PCA anal-
ysis resulted in an AUC of 0.87 while the CART model produced an AUC of 0.91. In terms 
of classification utility, the PCA model showed very good sensitivity (0.80) and good spec-
ificity (0.70), with high negative predictive value (0.824) and moderately high positive 
predictive value (0.667) at the combined sample base rate. The CART model demonstrated 
excellent sensitivity (1.00) and very good specificity (0.810), with excellent negative pre-
dictive value (1.00) and high positive predictive value (0.778) at the combined sample base 
rate. 
 
Figure 2. ROC curve comparison for PCA versus CART derived models. PCA area under the curve 
(AUC) = 0.87, and CART model AUC = 0.91. 




The present data indicate that for adults with DS, variability in orientation, language, 
memory, visuospatial skills, praxis, mood, and social participation is largely explained by 
two underlying principal components. These two components seemed to differentiate 
cognitive from practical function (i.e., the ability to answer questions vs. the ability to 
carry out everyday tasks). Additionally, the use of the two-component model to catego-
rize participants with respect to AD dementia status showed high classification accuracy. 
These findings support the further distillation of the modest-sized battery into a “short 
form” that can be easily administered in a primary care setting. Additionally, it takes less 
than an hour to administer to an informant who knows the patient with DS well, and 
requires minimal office space and test stimuli. 
Results of the CART analysis also demonstrated that a small subset of the original 
battery—the cognitive subscale of the DLD (SCS) and the community subscale of the Vine-
land-II—were just as effective in classifying AD dementia status. However, the CART 
model exhibited better negative predictive value, in that fewer participants with dementia 
were misclassified as non-demented compared to the principal components model. A 
short battery based on the CART model is also quicker to administer and can in most cases 
be completed in less than 30 min. 
A key finding is that the two contributory measures are not direct, objective measures 
of cognitive performance completed by the patient. Instead, they are informant-based 
scores of the patient’s observed changes in cognitive abilities (DLD-SCS) and self-man-
agement in community tasks (Vineland-II community). Unexpectedly, classification did 
not appreciably hinge on objective, performance-based neurocognitive measures. This 
highlights the critical component of informed caregiver ratings when screening for de-
mentia in DS populations and provides some assurance that differential diagnosis of AD 
dementia is still possible when a patient’s cognitive abilities cannot be directly assessed 
due to profound ID, limited cooperation, sensory impairments, or speech and language 
disorders. 
Overall, the present data suggest that in clinical contexts with limited time and access 
to advanced training in test administration, the cognitive subscale of the DLD and com-
munity subscale of the Vineland-II, two widely available instruments, may suffice for 
screening and monitoring purposes. To be clear, we do not conclude that these two sub-
scales constitute a comprehensive research or diagnostic battery, as definitive diagnosis 
should be based on longitudinal data. Nor is it the case that objective neurocognitive per-
formance measures are redundant for diagnostic purposes. On the contrary, diagnostic 
criteria require objective neurocognitive assessment in order to make a firm diagnosis [33]. 
The present analysis was conducted for the specific aims of the study, namely identifying 
measures for resource-limited healthcare settings to encourage wide adoption of demen-
tia screening among community DS practitioners. Prior efforts to use data reduction ap-
proaches to streamline a cognitive and behavioral battery for dementia in DS were focused 
primarily on developing a minimal comprehensive battery for research and specialty eval-
uation settings; thus, the resulting recommendations were not as relevant to primary care 
screening [38]. 
Furthermore, the present findings do not suggest that these two subscales represent 
an advancement in the early detection of AD dementia relative to more comprehensive 
test batteries. Instead, the benefit of adopting a minimal screening battery would enable 
more of the broader DS population to be evaluated, who may otherwise go unassessed. 
At the individual level, “early” detection is relative to the person’s typical access to care, 
not the recommended standard of care. Given that nearly half of adults with DS do not 
receive regular screening for typical DS-associated health problems [11], it is reasonable 
to cast a wider net with “good enough” measures easily administered in primary care 
settings. Moreover, operating characteristics of the CART model align with a preference 
for high sensitivity (potential over-identification) over high specificity because the goal of 
screening is to provide support to this population. 
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Examination of the factor structure and of the item- and subscale-level operating 
characteristics in diagnostic batteries for dementia in DS is relatively new ground, and it 
is difficult to contextualize the present findings in the literature on the constructs meas-
ured. Broadly speaking, these data are in line with indications that adults with DS have 
reduced—but not absent—functional independence relative to other adults with intellec-
tual disabilities [39], and dementia-related impairment in that domain may be captured 
by a community functioning measure such as the Vineland-II community subscale. Prior 
work using the Vineland-II to predict AD dementia in DS found that informant-rated re-
ceptive language skills, in addition to performance on a semantic verbal fluency task, were 
strong indicators of mild cognitive impairment in DS [40]. The present analysis instead 
examined individuals with and without AD dementia and found community manage-
ment skills to be the most informative subscale of the Vineland-II. These findings are not 
contradictory, as in the present study it is likely that variability between participants cog-
nitive functioning were captured by the DLD-SCS informant-based score, leaving more 
contextual community-based functioning to be best represented by the Vineland-II com-
munity subscale. 
Beyond those discussed above, additional limitations of this study include the use of 
the SIB, DLD, and BPT along with the neurologic examination to determine consensus 
diagnosis. Our prior investigations have found that in 96% of cases, the final consensus 
diagnosis matched the neurologist’s diagnosis that was formed independently of the SIB, 
BPT, and DLD scores. Still, discussion with the informant allows exposure to much of the 
same information captured by these instruments, and consideration of this information 
when forming a diagnosis is unavoidable. The eventual goal of both study cohorts is to 
substantiate consensus diagnoses with neuropathology at autopsy, allowing a more direct 
evaluation of the influence of potential criterion contamination. Additionally, the present 
study relied on informants who were very familiar with the participants with DS being 
rated, and in many cases, such a source of information cannot be found in practice. 
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